Clinical Trials Browser

Phase 2/3 × Tyrosine Kinase Inhibitors × Tumor-Agnostic × Clear all

NCT03624530 2018-08-10

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Phase 2/3 Unknown

Neoplasm, Residual